undamentalytics Newsletter
Sign in

Sinovac Biotech LTD balance sheet

At the end of fiscal 2025, Sinovac Biotech LTD had total assets of $8.54bn, total liabilities of $2.15bn and shareholders' equity of $4.44bn. It held $488m in cash against $495m of debt: net debt of $6.6m.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents0.10.10.10.10.10.20.21.011.63.91.10.30.5
Receivables—0.00.00.00.10.10.10.30.90.50.40.30.3
Inventory—0.00.00.00.00.00.00.10.40.20.10.10.1
Total current assets—0.10.10.10.20.30.31.614.911.311.610.67.1
Goodwill————————0.00.00.00.00.0
Total assets—0.20.20.20.30.40.51.916.814.013.612.38.5
Deferred revenue (current)——0.00.00.00.00.00.40.10.00.00.00.0
Total current liabilities—0.00.00.10.10.10.10.72.51.31.31.51.5
Short-term debt———0.00.00.0———————
Long-term debt———0.00.00.00.00.00.00.00.30.40.5
Total debt0.00.0—0.00.00.00.00.00.00.00.30.40.5
Total liabilities—0.10.10.10.10.10.10.83.21.82.02.02.1
Shareholders' equity0.10.10.10.10.20.30.30.79.08.58.38.34.4
Non-controlling interests and other (assets − liabilities − equity)—0.00.00.00.00.00.10.44.63.83.32.02.0
Net debt (negative = net cash)−0.1−0.1−0.1−0.0−0.1−0.2−0.1−1.0−11.6−3.9−0.90.00.0
Shares outstanding—54m55m57m57m71m99m99m72m72m72m72m72m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: MNKD vs SVAPHAR vs SVAMGTX vs SVANVAX vs SVA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sinovac Biotech LTD's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Sinovac Biotech LTD.